Breast Cancer Clinical Trials in Midlothian, Virginia

6 studies are recruiting for breast cancer in Midlothian, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Bon Secours Westchester Emergency Center, Midlothian, Virginia

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

2. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

   This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Midlothian, Virginia

   Locations

   320 in total

   Run by

   AstraZeneca

   See if you can join NCT06103864 on ClinicalTrials.gov

3. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

   This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Trial Site, Midlothian, Virginia

   Locations

   181 in total

   Run by

   Olema Pharmaceuticals, Inc.

   See if you can join NCT07085767 on ClinicalTrials.gov

4. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Bon Secours Saint Francis Medical Center, Midlothian, Virginia

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

5. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

   This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Bon Secours St. Francis Medical Oncology Center, Midlothian, Virginia

   Locations

   203 in total

   Run by

   Celcuity Inc

   See if you can join NCT06757634 on ClinicalTrials.gov

6. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Bon Secours Cancer Institute at St. Francis, Midlothian, Virginia

   Locations

   58 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov